The purpose of this study is to evaluate how well maribavir works in treating cytomegalovirus infection in these patients and to assess what side effects might lead to stopping the treatment. The study will measure success by checking whether the amount of virus in the blood drops to very low levels that cannot be easily measured after eight weeks of treatment. The medication is taken by mouth in the form of film-coated tablets, with a maximum daily dose of 800 milligrams, and treatment can continue for up to twelve weeks.

During the study, patients will have regular blood tests to measure the amount of virus in their blood and to monitor for any side effects. The study will track how many patients respond to the treatment within eight weeks and will also follow patients for an additional eight weeks after they stop taking the medication to see if the virus returns. Some patients who show partial improvement at eight weeks may continue treatment for up to twelve weeks to see if they achieve a better response. The study will also record any side effects that occur during treatment, particularly those that are serious enough to require stopping the medication.

The purpose of this study is to find better ways to perform stem cell transplants in young patients with acute lymphoblastic leukemia by reducing side effects and complications while still keeping the transplant effective at preventing the cancer from coming back. The study will test different approaches, including whether a lower dose of radiation works as well as a higher dose, whether adding ruxolitinib to steroids helps treat a complication called graft-versus-host disease, which happens when the donor cells attack the patient’s body, and whether giving blinatumomab after transplant helps prevent the cancer from returning in very young children. The study will also compare different types of donors and different ways to prepare patients for transplant.

Patients will be followed for several years after their transplant to see how well the treatments work. During the study, patients will receive their transplant preparation treatment over several days, followed by the stem cell transplant itself. Some patients may receive additional treatment after transplant depending on which part of the study they are in. For example, patients receiving ruxolitinib for graft-versus-host disease may take this medicine for up to 24 weeks, while very young children may receive up to four cycles of blinatumomab treatment after their transplant. Throughout the study, patients will have regular check-ups and tests to monitor their progress and watch for any side effects or complications.

The purpose of the study is to see if FMT can help prevent complications after the stem cell transplant. Specifically, the study aims to improve the chances of patients staying free from a condition called graft-versus-host disease (GVHD) and cancer relapse for one year after their transplant. GVHD is a condition where the donor’s immune cells attack the patient’s body. The study will compare the effects of FMT with no additional treatment to see if it makes a difference in patient outcomes.

Participants in the study will receive the FMT treatment and be monitored over time to assess their health and any side effects. The study will look at various factors, including overall survival, the occurrence of infections, and the quality of life of the patients. The goal is to determine if FMT can be a safe and effective way to support patients after their stem cell transplant and improve their long-term health.

The purpose of the study is to evaluate how well these vaccines work in helping the immune system of transplant recipients respond to RSV. Participants will be randomly assigned to receive either the Arexvy or Abrysvo vaccine. The study will monitor the participants’ immune response to the vaccine, specifically looking for a significant increase in antibodies, which are proteins the body makes to fight infections. The study will also include a group of healthy older adults to compare their immune responses to those of the transplant recipients.

Participants will receive the vaccine through an intramuscular injection, which means it will be given as a shot into a muscle. The study will take place over several months, with participants receiving one or two doses of the vaccine, depending on their initial response. The goal is to understand how effective the vaccines are in preventing RSV infections in people who have had a stem cell transplant and to identify any patterns in the immune response that could predict how well someone might respond to the vaccine.

The purpose of the study is to evaluate how effective Ivosidenib is in improving the time patients remain free from events like disease relapse or death. Participants in the study will receive Ivosidenib as a maintenance therapy for up to 24 months after undergoing a procedure called allogeneic stem cell transplantation (alloSCT), which involves receiving healthy stem cells from a donor. The study will compare the outcomes of patients taking Ivosidenib with those who do not receive this treatment.

Throughout the study, participants will be monitored for various outcomes, including their overall survival and the rate at which they remain free from disease events. The study will also track any side effects or complications that may arise from the treatment. This research aims to provide valuable insights into the potential benefits of Ivosidenib for patients with AML or HR-MDS who have the IDH1 mutation.

Participants in the study will be randomly assigned to receive either fosfomycin or ciprofloxacin. Both medications are taken orally, meaning they are swallowed in pill form. The study will monitor the participants over a period of time to see how well each medication works in preventing febrile neutropenia and to ensure the safety of the participants. The goal is to determine if fosfomycin is as effective as ciprofloxacin in preventing infections in these patients.

The study is designed to help improve treatment options for patients with acute leukemia who are at high risk of developing infections due to their weakened immune systems. By comparing these two antibiotics, researchers hope to find the best approach to prevent febrile neutropenia and improve the overall care for patients undergoing chemotherapy or stem cell transplants.

The purpose of the study is to determine the safest dose of iG-Tregs and to evaluate their safety when used in patients who have received a transplant from a fully compatible sibling donor. The study will also look at how well these cells work in preventing GvHD. Participants will receive the iG-Tregs injection and will be monitored for any side effects or reactions. The study will compare the results of patients receiving iG-Tregs with those who do not receive this treatment.

Throughout the study, patients will be closely observed for any signs of GvHD and other potential side effects. The study will last for a period of time to ensure that the treatment is safe and effective. The goal is to find a dose that is both safe and effective in preventing GvHD, while also assessing the overall health and recovery of the patients after their transplant.

The purpose of the study is to evaluate the safety and effectiveness of SMART101 in patients who have received a stem cell transplant from a donor whose tissue type does not completely match their own. The study will be conducted in two segments. In the first segment, researchers will determine the best dose of SMART101 to use. In the second segment, they will assess how safe the treatment is and how well it works in helping the immune system recover, particularly focusing on the reconstitution of CD4+ T-cells, which are important for fighting infections.

Participants in the study will receive the SMART101 treatment after their stem cell transplant, along with a medication called cyclophosphamide, which is used to help prevent complications. The study will monitor participants for any unexpected side effects and measure how well their immune system recovers over time. The goal is to find out if SMART101 can make stem cell transplants safer and more effective for patients with blood cancers.

The purpose of this research is to examine how safe and effective cord blood transplantation is when the blood cells have been treated with a special expansion process. The treatment involves giving patients an intravenous infusion of these processed cord blood cells. The study will look at how well patients recover after receiving the transplant and track their health for up to two years afterward.

During the study, patients will receive the cord blood cells that have been processed using a technique to increase their number. After the transplant, doctors will monitor how well the new cells establish themselves in the patient’s body and check for any complications. The study will track various aspects of recovery, including how quickly the blood counts return to normal and whether there are any immune system reactions.

The purpose of the study is to compare the body’s response to the Gardasil 9 vaccine when given at two different times after the stem cell transplant: either starting at 9 months or at 15 months post-transplant. Participants will receive the vaccine as a series of injections, and the study will monitor how well their immune system responds to the vaccine over time.

Throughout the study, participants will receive three doses of the vaccine, and their antibody levels, which are proteins the body makes to fight infections, will be measured at different intervals. This will help researchers understand how effective the vaccine is when given at different times after the transplant. The study aims to provide valuable information on the best timing for vaccination to ensure optimal protection against HPV for those who have had an allogeneic stem cell transplantation.

The purpose of the study is to understand how well posaconazole works in preventing fungal infections in these patients. Participants will receive posaconazole for a period of time, and the study will monitor how much of the drug remains in their blood after a week of treatment. This helps to determine if the medication is being absorbed properly and is at a level that can effectively prevent infections. The study will also keep track of any side effects or issues with taking the medication, as well as the overall health and recovery of the patients during and after the treatment period.

Throughout the study, patients will be closely monitored by healthcare professionals. This includes regular check-ups to assess any symptoms that might suggest problems with absorbing the medication, such as nausea or diarrhea. The study will also look at how well patients stick to their treatment plan and any other medications they might be taking. The goal is to ensure that posaconazole is safe and effective for preventing fungal infections in patients undergoing stem cell transplants.

The study tests whether adding itolizumab to corticosteroid treatment works better than adding placebo to corticosteroids for patients with Acute Graft Versus Host Disease. The medication is given through an intravenous infusion (delivered directly into a vein) over a period of 84 days. The total amount of medication given depends on the patient’s weight.

During the study, participants receive either itolizumab (given as EQ001 solution for infusion) or a matching placebo along with corticosteroid treatment. The study uses specific methods to ensure neither the doctors nor the patients know which treatment each person receives. The main goal is to see how well patients respond to the treatment, particularly in the early stages of the disease.

The purpose of the study is to explore how effective Letermovir is in preventing CMV infection in these specific transplant patients. Participants in the study will take Letermovir for a period of up to 14 weeks. During this time, the study will monitor the occurrence of CMV infection and any need for additional treatment. The study will also observe other health outcomes, such as the recovery of blood cells and any side effects related to the medication.

Throughout the study, participants will be regularly checked by healthcare professionals to ensure their safety and to gather information on how well Letermovir works in preventing CMV infection. The study aims to provide valuable insights into the use of Letermovir for CMV prevention in patients who have undergone an allogeneic stem cell transplant.

Participants in the study will receive these medications intravenously, meaning they are given directly into a vein. The study will monitor the cumulative exposure to F-Ara-A, which means the total amount of this substance that the body is exposed to over time. The study will also look at how this exposure varies between different patients. This information will help researchers understand how the body processes these medications and how this might affect the outcomes of the transplant.

The study will follow patients over a period of time to observe various outcomes, such as survival rates and the body’s ability to recover blood cell counts after the transplant. Researchers will also examine how factors like body weight and kidney function might influence the levels of F-Ara-A in the body. This trial aims to gather important data that could improve the treatment process for patients undergoing stem cell transplants in the future.

The purpose of the study is to evaluate how effective this low-dose treatment is in preventing GVH in older patients who have received this type of transplant. The study will follow patients over a period of time to monitor their health and any side effects they may experience. Patients will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study will track the occurrence of GVH and other health outcomes at various points in time after the transplant, such as 30, 60, 90, and 100 days, and up to one year.

Throughout the study, researchers will also look at other important health measures, such as the number of certain immune cells in the blood, the incidence of infections, and overall survival rates. The quality of life of participants will be assessed using a questionnaire designed for patients who have undergone bone marrow transplants. This study aims to provide valuable information on how to better protect patients from GVH and improve their overall outcomes after a stem cell transplant.

The purpose of the study is to compare the effectiveness of MaaT033 with a placebo in improving overall survival rates at 12 months after the treatment begins. Participants in the study will be randomly assigned to receive either MaaT033 or a placebo, which is a capsule that looks like the treatment but does not contain the active substance. The study is conducted in a way that neither the participants nor the researchers know who is receiving the actual treatment or the placebo, ensuring unbiased results.

Throughout the study, participants will take the medication orally, and their health will be monitored over a period of time to assess the treatment’s impact on their survival and any potential side effects. The study aims to provide valuable information on whether MaaT033 can effectively prevent complications in patients undergoing alloHCT, potentially leading to better outcomes for those with blood cancers.

Participants in the study will receive either semaglutide or a placebo, which is a substance with no active medication. The treatment will be administered as a solution for injection using a pre-filled pen. The study will monitor the participants over a period of time to assess the intensity of gastrointestinal mucositis and other related health factors. The goal is to determine if semaglutide can effectively reduce the discomfort and complications associated with this condition during the chemotherapy and transplantation process.

Throughout the study, researchers will also evaluate other aspects such as changes in inflammation levels and quality of life. The safety of semaglutide will be closely monitored to ensure it is well-tolerated by participants. This trial is an important step in exploring new ways to improve the treatment experience and outcomes for patients undergoing high-dose chemotherapy and stem cell transplantation.